Vaccination with recombinant 4×M2e.HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens

Veterinary Microbiology

Volumn 174, Issue 1-2, 2014, Pages 116-126

  Dabaghian, Mehran ^a,b   Latify, Ali Mohammad ^a   Tebianian, Majid ^c   Nili, Hassan ^d   Ranjbar, Ali Reza Tevangar ^e   Mirjalili, Ali ^c   Mohammadi, Mashallah ^c   Banihashemi, Reza ^f   Ebrahimi, Seyyed Mahmoud ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF TEHRAN   (Iran)

^c RAZI VACCINE AND SERUM RESEARCH INSTITUTE   (Iran)

^d SHIRAZ UNIVERSITY   (Iran)

^e IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Chicken; H9N2; HSP70c; Influenza A universal vaccine; M2e

Indexed keywords

GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; INFLUENZA VACCINE; INTERLEUKIN 4; MATRIX PROTEIN; RECOMBINANT MATRIX PROTEIN 2E HEAT SHOCK PROTEIN 70C FUSION PROTEIN; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; HYBRID PROTEIN; INACTIVATED VACCINE;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHICKEN; CONTROLLED STUDY; CROSS PROTECTION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; HEMAGGLUTINATION INHIBITION; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA A; INFLUENZA A (H9N2); INFLUENZA VACCINATION; INFLUENZA VIRUS A H9N2; LYMPHOCYTE PROLIFERATION; NONHUMAN; PERIPHERAL LYMPHOCYTE; PROVOCATION TEST; TANDEM REPEAT; TH1 CELL; TH2 CELL; VIRAL CLEARANCE; VIRUS IMMUNITY; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TITRATION; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEMAGGLUTINATION TEST; IMMUNOLOGY; IMMUNOPHENOTYPING; INFLUENZA IN BIRDS; INTRAMUSCULAR DRUG ADMINISTRATION; POULTRY DISEASES; RANDOMIZED CONTROLLED TRIAL; VACCINATION; VETERINARY; VIROLOGY;

ANIMALS; CHICKENS; CROSS PROTECTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEMAGGLUTINATION TESTS; HSP70 HEAT-SHOCK PROTEINS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOPHENOTYPING; INFLUENZA A VIRUS, H9N2 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; INTERLEUKIN-4; POULTRY DISEASES; RECOMBINANT FUSION PROTEINS; VACCINATION; VACCINES, INACTIVATED; VIRUS SHEDDING;

EID: 84909982991     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2014.09.009     Document Type: Article

References (53)

1. Alexander D.J. Report on avian influenza in the Eastern Hemisphere during 1997-2002. Avian Dis. 2003, 47:792-797.
2. Arnold D., Raath S., Rammensee H.G., Schild H. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J. Exp. Med. 1995, 182:885.
3. Bano S., Naeem K., Malik S.A. Evaluation of pathogenic potential of avian influenza virus serotype H9N2 in chickens. Avian Dis. 2003, 47:817-822.
4. Betakova T. M2 protein-a proton channel of influenza A virus. Curr. Pharm. Des. 2007, 13:3231-3235.
5. Blachere N.E., Li Z., Chandawarkar R.Y., Suto R., Jaikaria N.S., Basu S., et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med. 1997, 186:1315.
6. Boni M.F. Vaccination and antigenic drift in influenza. Vaccine 2008, 26:C8-C14.
7. Brett I.C., Johansson B.E. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology 2005, 339:273-280.
8. Chen J., Zhang F., Fang F., Chang H., Chen Z. Vaccination with hemagglutinin or neuraminidase DNA protects BALB/c mice against influenza virus infection in presence of maternal antibody. BMC Infect. Dis. 2007, 7:118.
9. Choi J.G., Lee Y.J., Kim Y.J., Lee E.K., Jeong O.M., Sung H.W., et al. An inactivated vaccine to control the current H9N2 low pathogenic avian influenza in Korea. J. Vet. Sci. 2008, 9:67-74.
10. Ebrahimi S.M., Dabaghian M., Tebianian M., Zabeh Jazi M.H. In contrast to conventional inactivated influenza vaccines 4×M2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran. Virology 2012, 430:63-72.
11. Ebrahimi S.M., Ziapour S., Tebianian M., Dabaghian M., Mohammadi M. Study of infection with an Iranian field-isolated H9N2 avian influenza virus in vaccinated and unvaccinated Japanese quail. Avian Dis. 2011, 55:195-200.
12. Ernst W.A., Kim H.J., Tumpey T.M., Jansen A.D., Tai W., Cramer D.V., et al. Protection against H1, H5, H6 and H9 influenza A infection with Liposomal matrix 2 epitope vaccines. Vaccine 2006, 24:5158-5168.
13. Fabrice C., Vergu E., Ferguson N.M., Lemaitre M., Cauchemez S., Leach S., Valleron A.J. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am. J. Epidemiol. 2008, 167:775-785.
14. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22:2993-3003.
15. Fan W., Huang J.H., Yuan X.Y., Huang W.H., Chen Y.H. Characterization of immunity induced by M2e of influenza virus. Vaccine 2007, 25:8868-8873.
16. Fiers W., De Filette M., Birkett A., Neirynck S., Min Jou W. A "universal" human influenza A vaccine. Virus Res. 2004, 103:173-176.
17. Frace A.M., Klimov A.I., Rowe T., Black R.A., Katz J.M. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 1999, 17:2237-2244.
18. Furuya Y., Chan J., Regner M., et al. Cytotoxic T cells are the predominant players providing cross-protective immunity induced by gamma-irradiated influenza A viruses. J. Virol. 2010, 84:4212-4221.
19. Huleatt J.W., Valerian N., Priyanka D., Yan H., Duane H., Andrea J., et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26:201-214.
20. Jegerlehner A., Schmitz N., Storni T., Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 2004, 172:5598-5605.
21. Kishida N., Sakoda Y., Eto M., Sunaga Y., Kida H. Co-infection of Staphylococcus aureus or Haemophilus paragallinarum exacerbates H9N2 influenza A virus infection in chickens. Arch. Virol. 2004, 149:2095-2104.
22. Kong X., Hu Y., Rui R., Wang D., Li X. Effects of Chinese herbal medicinal ingredients on peripheral lymphocyte proliferation and serum antibody titer after vaccination in chicken. Int. Immuno. Pharmacol. 2004, 4:975-982.
23. Layton S., Kapczynski D.R., Higgins S., Higgins J., wolfenden A.D., et al. Vaccination of chickens with recombinant Salmonella expressing M2e and CD154 epitopes increases protection and decreases viral shedding after low pathogenic avian influenza challenge. Poult. Sci. 2009, 88:2244-2252.
24. Le Gall-Reculé G., Cherbonnel M., Pelotte N., Blanchard P., Morin Y., Jestin V. Importance of a prime-boost DNA/protein vaccination to protect chickens against low-pathogenic H7 avian influenza infection. Avian Dis. 2007, 51:490-494.
25. Lincoln L.H.L., Benjamin J.C., Vicky J.F., Chan K.H., Eric H.Y.L., et al. Viral shedding and clinical illness in naturally acquired influenza virus infections. J. Infect. Dis. 2010, 201:1509-1516.
26. Liu W., Zou P., Ding J., Lu Y., Chen Y.H. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect. 2005, 7:171-177.
27. Misplon J.A., Lo C.Y., Gabbard J.D., Tompkins S.M., Epstein S.L. Genetic control of immune responses to influenza A matrix 2 protein (M2). Vaccine 2010, 28:5817-5827.
28. Moscona A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 2005, 353:1363-1373.
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application of proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
30. Mozdzanowska K., Feng J., Eid M., Kragol G., Cudic M., Gerhard W., et al. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 2003, 21:2616-2626.
31. Mozdzanowska K., Maiese K., Furchner M., Gerhard W. Treatment of influenza virus-infected SCID mice with non-neutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 1999, 254:138-146.
32. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 1999, 5:1157-1163.
33. Qiu M., Fang F., Chen Y., Wang H., Chen Q., Chang H., Wang F., et al. Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin or neuraminidase-expressing DNA in BALB/c mice. Biochem. Biophys. Res. Commun. 2006, 343:1124-1131.
34. Reed L.J., Muench H.A. Simple method for estimating fifty per cent endpoints. Am. J. Hyg. 1938, 27:493-497.
35. Sealy R., Surman S., Hurwitz J.L., Coleclough C. Antibody response to influenza infection of mice: different patterns for glycoprotein and nucleocapsid antigens. Immunology 2003, 108:431-439.
36. Senne D.A. Avian influenza in the western Hemisphere including the Pacific Islands and Australia. Avian Dis. 2003, 47:798-805.
37. Slepushkin V.A., Katz J.M., Black R.A., Gamble W.C., Rota P.A., Cox N.J. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 1995, 13:1399-1402.
38. Song J.M., Wang B.Z., Park K.M., Van R.N., Quan F.S., Kim M.C., et al. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 2011, 6:e14538.
39. Spackman E., Gelb J., Preskenis L.A., Ladman B.S., Pope C.R., Pantin-Jackwood M.J., et al. The pathogenesis of low pathogenicity H7 avian influenza viruses in chickens, ducks and turkeys. Virol. J. 2010, 7:331.
40. Stevens T.L., Bossie A., Sanders V.M., Fernandez-Botran R., Coffman R.L., Mosmann T.R., et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988, 334:255-258.
41. Subbarao K., Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat. Rev. Immunol. 2007, 7:267-278.
42. Sun Y., Pu J., Fan L., Sun H., Wang J., Zhang Y., et al. Evaluation of the protective efficacy of a commercial vaccine against different antigenic groups of H9N2 influenza viruses in chickens. Vet. Microbiol. 2012, 156:193-199.
43. Swayne D.E., Halvorson D.A. Influenza. Diseases of Poultry 2003, 132-160. Iowa State University Press, Ames, IA. Y.M. Saif, H.J. Barnes, J.R. Glisson, A.M. Fadly, L.R. McDougald, D.E. Swayne (Eds.).Diseases of Poultry. Iowa State University Press, Ames, IA, pp. 132-160.
44. Takakura Y., Takemoto S., Nishikawa M. Hsp-based tumor vaccines: state-of-the-art and future directions. Curr. Opin. Mol. Ther. 2007, 9:385-391.
45. Takemoto S., Nishikawa M., Takakura Y. Pharmacokinetics and tissue distribution mechanism of mouse recombinant heat shock protein 70 in mice. Pharm. Res. 2005, 22:419-426.
46. Tobian A.A.R., Canaday D.H., Boom W.H., Harding C.V. Bacterial heat shock proteins promote CD91-dependent class I MHC cross-presentation of chaperoned peptide to CD8T cells by cytosolic mechanisms in dendritic cells versus vacuolar mechanisms in macrophages. J. Immunol. 2004, 172:5277.
47. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg. Infect. Dis. 2007, 13:426-435.
48. Unkeless J.C., Scigliano E., Freedman V.H. Structure and function of human and murine receptors for IgG. Annu. Rev. Immunol. 1988, 6:251-281.
49. Wareing M.D., Tannock G.A. Live attenuated vaccines against influenza; an historical review. Vaccine 2001, 19:3320-3330.
50. Wu F., Huang J.H., Yuan X.Y., Huang W.S., Chen Y.H. Characterization of immunity induced by M2e of influenza virus. Vaccine 2007, 25:8868-8873.
51. Wu F., Yuan X.Y., Li J., Chen Y.H. The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine. Vaccine 2009, 27:4320-4324.
52. Zabeh Jazi M.H., Dabaghian M., Tebianian M., Gharagozlou M.H., Ebrahimi S.M. In vivo electroporation enhances immunogenicity and protection against influenza A virus challenge of an M2e-HSP70c DNA vaccine. Virus Res. 2012, 167:219-225.
53. Zhao G., Du L., Xiao W., Sun S., Lin Y., Chen M., et al. Induction of the protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. Vaccine 2010, 28:7233-7240.